Cargando…

Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy

BACKGROUND: Luminal A breast cancer has a good prognosis and the criteria for adjuvant and neoadjuvant chemotherapy (NAC) are not clear. The aim of this study was to present our results of upfront surgery and long-term survival in luminal A tumors as well as the rates of protection from axillary dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yüksel, Cemil, Aksel, Bülent, Doğan, Lütfi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356774/ https://www.ncbi.nlm.nih.gov/pubmed/35974878 http://dx.doi.org/10.1155/2022/8284814

Ejemplares similares

Breast cancer in older woman: can axillary dissection be omitted?
por: Barberini, Francesco, et al.
Publicado: (2009)

Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?
por: You, Ji Young, et al.
Publicado: (2023)

Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
por: Damle, Sameer, et al.
Publicado: (2009)

Population-Level Impact of Omitting Axillary Lymph Node Dissection in Early Breast Cancer Women: Evidence from an Economic Evaluation in Germany
por: Nguyen, Hoa Thi, et al.
Publicado: (2022)

Axillary Lymph Node Dissection Can Be Omitted in Breast Cancer Patients With Mastectomy and False-Negative Frozen Section in Sentinel Lymph Node Biopsy
por: Si, Jing, et al.
Publicado: (2022)

Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation
por: Zhong, Ying, et al.
Publicado: (2020)

Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients
por: Pinto, C. S., et al.
Publicado: (2022)

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
por: Reitsamer, R., et al.
Publicado: (2021)

A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
por: Yang, Hanzhao, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
por: Erbes, Thalia, et al.
Publicado: (2014)

Axillary recurrences after sentinel node (SLN) biopsy without complete axillary dissection in breast cancer patients
por: Kristen, P, et al.
Publicado: (2005)

Omitted Acknowledgment
Publicado: (2020)

Reference Omitted
Publicado: (2023)

Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node‐positive breast cancer: How can we select patients?
por: van Zeeland, Marianne, et al.
Publicado: (2020)

Reply: Axillary recurrences after sentinel node (SLN) biopsy without complete axillary dissection in breast cancer patients
por: Reitsamer, R, et al.
Publicado: (2005)

Oncologic outcomes in breast cancer patients with metastatic nodes and pathological nodal response following neoadjuvant chemotherapy without axillary dissection: a literature review
por: Lim, Geok Hoon, et al.
Publicado: (2023)

Marking Techniques for Targeted Axillary Dissection Among Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy
por: Gante, Inês, et al.
Publicado: (2023)

The Feasibility of Omitting Postoperative Radiotherapy in Japanese Patients With Ductal Carcinoma In Situ of Breast Treated With Breast-Conserving Surgery
por: Nakashima, Akihiro, et al.
Publicado: (2023)

Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)
por: Garcia-Tejedor, Amparo, et al.
Publicado: (2023)

Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy
por: Ling, Diane C., et al.
Publicado: (2019)

Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
por: Choi, Hee Jun, et al.
Publicado: (2022)

Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up
por: Martelli, Gabriele, et al.
Publicado: (2010)

Breast-conserving surgery without axillary surgery and radiation versus mastectomy plus axillary dissection in elderly breast cancer patients: A retrospective study
por: Zhong, Ying, et al.
Publicado: (2023)

Survival and recurrence with or without axillary dissection in patients with invasive breast cancer and sentinel node metastasis
por: Sanvido, Vanessa Monteiro, et al.
Publicado: (2021)

Targeted axillary dissection in breast cancer by marking lymph node metastasis with a magnetic seed before starting neoadjuvant treatment
por: García-Moreno, Joaquín Luis, et al.
Publicado: (2019)

Higher Pathological Complete Response Rate of Less than 10 Total Axillary Lymph Nodes After Axillary Lymph Node Dissection Following Neoadjuvant Chemotherapy in Breast Cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022)

Patient on Multiple Hormone Replacement Therapy for Hip Arthroplasty: How to Omit Noise and Be Focused?
por: Patel, Gautham, et al.
Publicado: (2022)

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients
por: Straver, Marieke E., et al.
Publicado: (2010)

Should Intercepting Traps Be Omitted?
Publicado: (1912)

Complete axillary dissection without drainage for the surgical treatment of breast cancer: a randomized clinical trial
por: Freitas-Junior, Ruffo, et al.
Publicado: (2017)

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study
por: Wu, Si-Yu, et al.
Publicado: (2023)

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial
por: de Boniface, Jana, et al.
Publicado: (2017)

Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
por: Yuan, Qianqian, et al.
Publicado: (2021)

Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
por: Takatsuka, Daiki, et al.
Publicado: (2023)

Prospective Evaluation of the Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Negative Axillary Conversion after Neoadjuvant Chemotherapy
por: Lee, Hy-De, et al.
Publicado: (2015)

Dissection of Level III Axillary Lymph Nodes in Breast Cancer
por: Hu, Jiejie, et al.
Publicado: (2021)

An Omitted Radiological finding in the Pediatric Age Group: Physiological Sacroiliac Joint Vacuum Normal Variant
por: Doğan, Emrah, et al.
Publicado: (2021)

The feasibility of omitting irradiation to the contralateral lower neck in stage N1 nasopharyngeal carcinoma patients
por: Hu, Weixu, et al.
Publicado: (2013)

Improving the feasibility of MRI in clinically suspect arthralgia for prediction of rheumatoid arthritis by omitting scanning of the feet
por: Boer, Aleid C, et al.
Publicado: (2020)

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
por: Skarping, Ida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o8sifar8c15gdbrhc9bs77bf0v